28Nov 2023
Disitamab Vedotin Shows Efficacy and Safety in HER2-Positive Urothelial Carcinoma

Disitamab Vedotin Shows Efficacy and Safety in HER2-Positive Urothelial Carcinoma

A novel treatment, disitamab vedotin (DV), has shown promising results in a study evaluating its effectiveness and safety for patients with HER2-positive urothelial carcinoma resistant to standard therapies. DV demonstrated a 50.5% objective response rate in two phase II trials, with consistent efficacy in subgroups. The median duration of response was 7.3 months, and median progression-free survival and overall survival were 5.9 and 14.2 months, respectively. The treatment's safety profile was manageable, with common adverse events including peripheral sensory neuropathy and leukopenia. Overall, DV shows potential for patients with advanced HER2-positive urothelial carcinoma.

  • #oncology

Like

Save

Share